Cochlear hair cell specific promoter and use thereof
By designing the core promoter elements of the Otov-HC and SHH genes, combined with the AAV vector system, the problems of instability in gene introduction and low transfection efficiency in cochlea hair cells are solved, and efficient expression and hearing recovery of deaf genes are achieved .
Patent Information
- Application Number
- PCT/CN2023/095739
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
The prior art has unstable expression and low transfection efficiency after gene introduction in cochlear hair cells, lack of targeting, and it is difficult to effectively treat sensorineural deafness.
A specific promoter Otov-HC is designed to combine the core promoter sequence and SHH gene to specifically guide gene expression in cochlear hair cells, and to introduce it into cochlear hair cells through the AAV vector system to achieve Stable and efficient expression of deaf genes.
The efficient and stable expression of genes in cochlea hair cells was achieved, and the effect of deaf gene therapy was significantly improved. Especially in the Otof gene knockout model, the hearing recovery effect was close to that of normal mice.
Smart Images

Figure 000031 
Figure 000032 
Figure 000033
Abstract
Description
Cochlear hair cell-specific promoter and use thereof Technical Field
[0001] The present invention relates to gene engineering technology, in particular to a method for gene therapy of cochlear hair cells. Background Art
[0002] Deafness is the most common sensory disorder in humans. According to the World Health Organization, deafness affects about 466 million people, including 34 million children, accounting for 6% of the world's population. Among them, sensorineural hearing loss (SNHL) accounts for about 63% of deaf patients. Sensorineural hearing loss is due to organic damage to the inner ear hair cells and auditory nerves, resulting in sound wave perception disorders, which in turn causes hearing loss. There are many causes of sensorineural hearing loss, including ototoxic drugs, noise, genetics and aging. The cause of congenital sensorineural hearing loss may be environmental factors (such as deafness caused by congenital cytomegalovirus and ototoxic antibiotics) or genetic factors. One in every 500 babies suffers from hereditary hearing loss, and 119 genes related to hereditary hearing loss have been identified. Non-syndromic deafness accounts for 60-70% of hereditary hearing impairment. Currently, more than 67 pathogenic genes for non-syndromic deafness have been identified, and the number of assigned non-syndromic deafness loci has reached 130. Among these 67 non-syndromic deafness genes, 38 are autosomal recessive genes, 25 are autosomal dominant genes, there are 2 X-chromosome-linked non-syndromic deafness genes, and the others are pathogenic genes for mitochondrial and microRNA-related deafness.
[0003] Cochlear hair cells, as sensory cells, primarily convert the mechanical vibrations of sound into bioelectrical signals. Currently, treatments for deafness primarily rely on medical assistance, with no effective alternatives other than hearing aids and cochlear implants. However, both hearing aids and cochlear implants are merely substitute treatments, with limited efficacy and incomparable functional outcomes to normal hearing. Ideal treatments for sensorineural hearing loss remain lacking.
[0004] Gene therapy involves manipulating genetic material to intervene in the development of a disease, treating it by replacing and correcting abnormal pathogenic genes. In recent years, with the deepening of research into the relationship between genetics and the pathogenesis of deafness, and the development of various animal models of deafness, a growing number of researchers have attempted to prevent and treat sensorineural hearing loss through gene therapy. In recent years, gene therapy has demonstrated significant potential in areas such as the protection and regeneration of auditory nerves and hair cells, and the treatment of hereditary hearing loss, and is expected to become an effective solution to the challenge of sensorineural hearing loss. Therefore, the development and application of gene transfer technology to restore normal cochlear function is urgent.
[0005] In recent years, gene therapy research for hereditary deafness has made significant breakthroughs. Several studies have reversed hearing phenotypes in hereditary deafness mouse models through gene therapy. Gene knockout mice for GJB2, VGLUT3, TMC, and KCNQ1 have all successfully retained partial hearing by introducing the corresponding wild-type genes into the cochlea. This series of research results suggests that gene therapy may become an effective treatment for hereditary deafness. While significant progress has been made in basic research on gene therapy for sensorineural hearing loss, clinical translation remains a long way off. Currently, one of the major obstacles to the clinical translation of gene therapy for deafness is the lack of stable and long-term expression of genes after delivery into cochlear hair cells, as well as low transfection efficiency and lack of targeting. Improving the transfection efficiency and targeting of genes into cochlear hair cells remains a hot topic for future research. Different promoters exhibit significant differences in expression levels within the same cell type, while specific promoters can express reporter genes specifically in different cell types. Currently, the nonspecific, ubiquitous CMV promoter, derived from human cytomegalovirus, and the CAG promoter, composed of the CMV enhancer and the chicken β-actin promoter, are commonly used for gene therapy. CMV transgene expression has been reported to decrease over time due to transcriptional silencing and lacks targeting. To achieve stable and relatively high specificity for cochlear hair cells, the design of specific promoters for deafness gene therapy is essential.
[0006] Summary of the Invention
[0007] In view of the shortcomings of the existing technology, the inventors developed a specific promoter Otov-HC (SEQ ID NO: 1), which can specifically promote the expression of transgenes in cochlear hair cells.
[0008] The present invention first provides a nucleic acid promoter, Otov-HC (SEQ ID NO: 1), which can specifically direct gene expression in cochlear hair cells as a promoter, comprising: (1) an enhancer sequence, and (2) a core promoter element, wherein the enhancer sequence has the sequence shown in SEQ ID NO: 2 or a homologous sequence having at least 90% sequence identity thereto and retaining the function of SEQ ID NO: 2. The homologous sequence is a sequence from mammals, preferably primates, and more preferably hominins.
[0009] In one or more embodiments, (2) the core promoter element is a core promoter element suitable for promoting gene expression in mammalian cells.
[0010] In one or more embodiments, (2) the core promoter element is the core promoter element of the SHH gene.
[0011] In one or more embodiments, (2) the core promoter element has the sequence shown in SEQ ID NO: 3 or a homologous sequence having at least 90% sequence identity thereto. The homologous sequence is the sequence of the core promoter element of the SHH gene of a mammal, preferably a primate, more preferably a hominid.
[0012] In one or more embodiments, (1) the enhancer sequence is located upstream or downstream of (2) the core promoter element.
[0013] In one or more embodiments, the distance between (1) the enhancer sequence and (2) the core promoter element is 0-5 kb, preferably 0-5 kb, 0-3 kb, 0-2 kb, 0-1 kb, 0-500 bp, more preferably 0-200 bp.
[0014] In one or more embodiments, the enhancer sequence is located 0-500 bp upstream of the core promoter element.
[0015] In one or more embodiments, the promoter comprises the sequence set forth in SEQ ID NO: 1 or a sequence having at least 90% sequence identity thereto.
[0016] The present invention also provides a nucleic acid construct comprising the promoter according to any embodiment of the present invention.
[0017] In one or more embodiments, the nucleic acid construct is an expression cassette. The expression cassette comprises the promoter, multiple cloning site and terminator from upstream to downstream (5' to 3'). Preferably, the terminator is a polyA terminator.
[0018] In one or more embodiments, the nucleic acid construct is a vector, such as a cloning vector, an integration vector, or an expression vector, preferably pAAV.
[0019] In one or more embodiments, the nucleic acid construct further comprises a gene of interest, which is operably linked to the promoter.
[0020] In one or more embodiments, the gene is selected from: a deafness gene, a tool gene for manipulating genes in cochlear hair cells, or a tool gene expressed in cochlear hair cells.
[0021] In one or more embodiments, the deafness gene is a deafness gene expressed by cochlear hair cells.
[0022] In one or more embodiments, the deafness gene is a causative gene for non-syndromic deafness.
[0023] In one or more embodiments, the deafness genes include one or more selected from the group consisting of ATOH1, VGLUT3, TMC1 / 2, KCNQ1, MLRB3, LHFPL5, OTOF, STRC, MYO7A, CHD7, TMPRSS3, POU3F4, ESPN, SYNE4, DIAPH1, KCNQ4, CEACAM16, MYO6, P2RX2, SMAC, TBC1D24, CD164, OSBPL2, HOMER2, MYO3A, PDE1C, SCD5, USH1C, RDX, DCD C2, LOXHD1, TPRN, SERPINB6, SiX1, CDH23, WHRN, OtoGL, WFS1, MYH9, REST, MCM2, DMXL2, TMIE, PCDH15, GRXC R1, TRIOBP, ILDR1, CIB2, GPSM2, ELMOD3, CABP2, TMEM132E, GRXCR2, EPS8, CLIC5, TRIOBP, ILDR1, SLC26A5.
[0024] The present invention also provides an AAV vector system, comprising the nucleic acid construct according to any embodiment of the present invention as pAAV and a nucleic acid construct encoding genes required for the AAV virus.
[0025] In one or more embodiments, the genes required for AAV virus packaging include one or more selected from the group consisting of Rep, Cap, E2A, E4, and VA genes.
[0026] In one or more embodiments, the AAV vector system comprises an AAV-ie plasmid, a pHelper plasmid, and the pAAV.
[0027] The present invention also provides an AAV virus particle comprising the promoter described in any embodiment herein.
[0028] The present invention also provides a host cell comprising or having integrated into its genome: the promoter, nucleic acid construct or AAV vector system described in any embodiment of the present invention.
[0029] Preferably, the cells are cochlear hair cells.
[0030] The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and one or more selected from the following: the promoter, nucleic acid construct, AAV vector system, AAV virus particle, and host cell described in any embodiment of the present invention.
[0031] The present invention also provides an in vitro method for expressing genes in cochlear hair cells, comprising the step of incubating the host cells according to any embodiment of the present invention under conditions suitable for gene expression, wherein the host cells are cochlear hair cells.
[0032] In one or more embodiments, the method further comprises the step of introducing a nucleic acid construct comprising the gene into cochlear hair cells.
[0033] In one or more embodiments, the expression of the gene is directed by the promoter, which is in the same expression frame as the gene and is located upstream of the gene.
[0034] In one or more embodiments, the gene is selected from: a deafness gene, various tool genes for manipulating genes of cochlear hair cells, or expressed in cochlear hair cells.
[0035] In one or more embodiments, the deafness gene is a deafness gene expressed by cochlear hair cells.
[0036] In one or more embodiments, the deafness gene is a causative gene for deafness.
[0037] In one or more embodiments, the deafness genes include one or more selected from the group consisting of ATOH1, VGLUT3, TMC1 / 2, KCNQ1, MLRB3, LHFPL5, OTOF, STRC, MYO7A, CHD7, TMPRSS3, POU3F4, ESPN, SYNE4, DIAPH1, KCNQ4, CEACAM16, MYO6, P2RX2, SMAC, TBC1D24, CD164, OSBPL2, HOMER2, MYO3A, PDE1C, SCD5, USH1C, RDX, DCDC2, LOXHD1, TPRN, SERPINB6, SiX1, CDH23, WHRN, OtoGL, WFS1, MYH9, REST, MCM2, DMXL2, TMIE, PC DH15, GRXCR1, TRIOBP, ILDR1, CIB2, GPSM2, ELMOD3, CABP2, TMEM132E, GRXCR2, EPS8, CLIC5, TRIOBP, ILDR1, SLC26A5.
[0038] The present invention also provides use of the promoter according to any embodiment of the present invention in the preparation of a drug for treating a disease caused by a gene defect in cochlear hair cells, wherein the drug is used to express the gene in cochlear hair cells.
[0039] In one or more embodiments, the gene is selected from: a deafness gene, various tool genes for manipulating genes of cochlear hair cells, or expressed in cochlear hair cells.
[0040] In one or more embodiments, the deafness gene is a deafness gene expressed by cochlear hair cells.
[0041] In one or more embodiments, the deafness gene is a causative gene for deafness.
[0042] In one or more embodiments, the deafness genes include one or more selected from the group consisting of ATOH1, VGLUT3, TMC1 / 2, KCNQ1, MLRB3, LHFPL5, OTOF, STRC, MYO7A, CHD7, TMPRSS3, POU3F4, ESPN, SYNE4, DIAPH1, KCNQ4, CEACAM16, MYO6, P2RX2, SMAC, TBC1D24, CD164, OSBPL2, HOMER2, MYO3A, PDE1C, SCD5, USH1C, RDX, DCDC2, LOXHD1, TPRN, SERPINB6, SiX1, CDH23, WHRN, OtoGL, WFS1, MYH9, REST, MCM2, DMXL2, TMIE, PCDH15, GRXCR1, TRIOBP, ILDR1, CIB2, GPSM2, ELMOD3, CABP2, TMEM132E, GRXCR2, EPS8, CLIC5, TRIOBP, ILDR1, SLC26A5.
[0043] In one or more embodiments, the disease is hereditary deafness caused by a genetic defect in cochlear hair cells. Preferably, the disease is sensorineural hearing loss. In one or more embodiments, the sensorineural hearing loss comprises congenital sensorineural deafness. In one or more embodiments, the congenital sensorineural deafness is congenital hereditary sensorineural deafness.
[0044] The present invention also provides a method for treating a disease caused by a gene defect in cochlear hair cells, comprising the step of expressing the gene in the cochlear hair cells of a subject, wherein the gene is operably linked to the promoter according to any embodiment of the present invention.
[0045] In one or more embodiments, the method includes the step of introducing into the cochlear hair cells a nucleic acid construct or vector comprising the coding sequence of the gene operably linked to the promoter.
[0046] In one or more embodiments, the expression of the gene is directed by the promoter, which is in the same expression frame as the gene and is located upstream of the gene.
[0047] In one or more embodiments, the gene is a deafness gene expressed by cochlear hair cells.
[0048] In one or more embodiments, the deafness gene is a causative gene for non-syndromic deafness.
[0049] In one or more embodiments, the deafness genes include one or more selected from the group consisting of ATOH1, VGLUT3, TMC1 / 2, KCNQ1, MLRB3, LHFPL5, OTOF, STRC, MYO7A, CHD7, TMPRSS3, POU3F4, ESPN, SYNE4, DIAPH1, KCNQ4, CEACAM16, MYO6, P2RX2, SMAC, TBC1D24, CD164, OSBPL2, HOMER2, MYO3A, PDE1C , SCD5, USH1C, RDX, DCDC2, LOXHD1, TPRN, SERPINB6, SiX1, CDH23, WHRN, OtoGL, WFS1, MYH9, REST, MCM2, DMXL2, TMIE, P CDH15, GRXCR1, TRIOBP, ILDR1, CIB2, GPSM2, ELMOD3, CABP2, TMEM132E, GRXCR2, EPS8, CLIC5, TRIOBP, ILDR1, SLC26A5.
[0050] In one or more embodiments, the disease is hereditary deafness caused by a genetic defect in cochlear hair cells. Preferably, the disease is sensorineural hearing loss. In one or more embodiments, the sensorineural hearing loss comprises congenital sensorineural deafness. In one or more embodiments, the congenital sensorineural deafness is congenital hereditary sensorineural deafness.
[0051] In one or more embodiments, the subject is a mammal, such as a mouse, rat, rabbit, dog, pig, monkey, or human, preferably a pig or human.
[0052] Beneficial effects of the present invention:
[0053] The promoter provided by the present invention can be specifically expressed in hair cells and can perform gene therapy for hearing loss caused by deafness gene mutation. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 shows the expression of a reporter gene driven by the broad-spectrum promoter CAG in cochlear cells.
[0055] A: P2 wild-type mice were injected with the AAV-ie-CAG-mNeonGreen-Bpnls virus (Bpnls is used to express mNeonGreen in the nucleus) through the round window. Two weeks later, cochlear samples were collected for immunofluorescence staining of the cochlear basilar membrane. The experiment shows CAG promoter-driven expression of the mNeonGreen reporter gene in cochlear hair cells. The mNeonGreen reporter gene co-labels with the hair cell marker Myosin7a, indicating widespread expression of the CAG promoter-driven reporter gene in cochlear hair cells.
[0056] B: A statistical diagram of the infection status of the mNeonGreen reporter gene in cochlear outer hair cells, indicating that the infection efficiency of the CAG promoter-driven reporter gene in cochlear outer hair cells (OHC) is close to 100%.
[0057] C: A statistical diagram of the infection status of the mNeonGreen reporter gene in cochlear inner hair cells, indicating that the infection efficiency of the CAG promoter-driven reporter gene in cochlear inner hair cells (IHC) is close to 100%.
[0058] D: P2 wild-type mice were injected with AAV-ie-CAG-mNeonGreen-Bpnls through the round window. Two weeks later, cochlear samples were collected for immunofluorescence staining of the cochlear basilar membrane. This assay shows CAG promoter-driven expression of the mNeonGreen reporter gene in cochlear supporting cells. Co-labeling of the mNeonGreen reporter gene with the supporting cell marker Sox2 demonstrates widespread expression of the CAG promoter-driven reporter gene in cochlear supporting cells (SCs).
[0059] E: A statistical diagram of the infection status of the mNeonGreen reporter gene in cochlear supporting cells, indicating that the infection efficiency of the CAG promoter-driven reporter gene in cochlear supporting cells (SC) can reach more than 75%.
[0060] Figure 2 shows immunofluorescence staining of the cochlea of newborn mice P3 after injection of the virus AAV-ie-Otov-HC-mNeonGreen through the round window. The cochlea was harvested on the 14th day after the injection. mNeonGreen was only expressed in the inner hair cells (IHC) and outer hair cells (OHC) of the cochlea, but not in the supporting cells (SC) and other cells.
[0061] A: P3 wild-type mice were injected with AAV-ie-Otov-HC-mNeonGreen-Bpnls through the round window. Two weeks later, cochlear samples were collected for immunofluorescence staining of the cochlear basilar membrane. The results show expression of the mNeonGreen reporter gene driven by the Otov-HC promoter in cochlear hair cells. The mNeonGreen reporter gene co-labeled with the hair cell marker Myosin7a, indicating that the Otov-HC promoter drives the reporter gene's expression exclusively in cochlear hair cells.
[0062] B: P3 wild-type mice were injected with AAV-ie-Otov-HC-mNeonGreen-Bpnls through the round window. Two weeks later, cochlear samples were collected for immunofluorescence staining of the cochlear basilar membrane. The results show expression of the mNeonGreen reporter gene driven by the Otov-HC promoter in cochlear hair cells. The mNeonGreen reporter gene co-labeled with the hair cell marker Myosin7a, indicating that the Otov-HC promoter drives the reporter gene's expression exclusively in cochlear hair cells.
[0063] C: P3 wild-type mice were injected with AAV-ie-Otov-HC-mNeonGreen-Bpnls through the round window. Two weeks later, cochlear samples were collected for immunofluorescence staining of the cochlear basilar membrane. The experiment shows expression of the mNeonGreen reporter gene in cochlear supporting cells driven by the Otov-HC-specific promoter. The mNeonGreen reporter gene does not co-label with the supporting cell marker Sox2, indicating that the Otov-HC-specific promoter does not drive reporter gene expression in cochlear supporting cells.
[0064] D: Statistical graph of the infection of mNeonGreen reporter gene driven by Otov-HC specific promoter in cochlear hair cells, indicating that the infection efficiency of Otov-HC specific promoter driven reporter gene in cochlear hair cells can reach 100%.
[0065] E: Statistical graph of the infection of the mNeonGreen reporter gene driven by the Otov-HC specific promoter in cochlear supporting cells, indicating that the infection efficiency of the reporter gene driven by the Otov-HC specific promoter in cochlear supporting cells is almost zero.
[0066] Figure 3 shows that the SHH sequence alone drives gene expression in cochlear cells.
[0067] A: Shows how the SHH sequence alone drives gene expression in cochlear hair cells.
[0068] B: Shows the situation where the SHH sequence alone drives gene expression in cochlear supporting cells.
[0069] Figure 4 shows the expression of the exogenous Otof gene driven by the Otov-HC specific promoter in the cochlear cells of OtofKO mice, indicating that the Otov-HC specific promoter drives the Otof gene to be specifically expressed only in the cochlear hair cells.
[0070] Figure 5 is a statistical diagram of the expression efficiency of the exogenous Otof gene driven by the Otov-HC specific promoter. The Otov-HC specific promoter drives the Otof gene to express at low and medium frequencies, and at high frequencies, the expression efficiency is above 55%.
[0071] Figure 6 shows the ABR results. They show that after Otof gene knockout, the hearing thresholds of mice increased significantly at low, mid, and high frequencies, indicating complete deafness. After dual-vector Otof gene therapy, ABR thresholds decreased, and hearing recovery was significantly restored across all frequency bands, with hearing recovery comparable to that of WT mice in their littermates. DETAILED DESCRIPTION
[0072] Unless otherwise defined, the practice of the present invention will employ conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. These techniques are fully explained in the literature, such as Molecular Cloning: A Laboratory Manual, Second Edition (Sambrook et al., 1989); Oligonucleotide Synthesis (MJ Gait, ed., 1984); Animal Cell Culture (RI Freshney, ed., 1987); Methods in Enzymology (Academic Press, Inc.); Current Protocols in Molecular Biology (FM Ausubel et al., eds., 1987 edition and periodic updates thereof); PCR: The Polymerase Chain Reaction (Mullis et al., eds., 1994); A Practical Guide to Molecular Cloning (Perbal Bernard V., 1988); Phage Display: A Laboratory Manual (Barbas et al., 2001).
[0073] Compared with the prior art, the present invention provides a treatment method that specifically targets cochlear hair cells: by using a promoter that can specifically target cochlear hair cells, a viral vector containing the promoter is used to deliver specific transgenes (such as ATOH1, VGLUT3, TMC1 / 2, KCNQ1, MLRB3, LHFPL5, OTOF, STRC, MYO7A, CHD7, TMPRSS3, POU3F4, ESPN, SYNE4, DIAPH1, KCNQ4, CEACAM16, MYO6, P2RX2, SMAC, TBC1D24, CD164, OSBPL2, HOMER2, MYO3A, PDE1C, SCD5, US H1C, RDX, DCDC2, LOXHD1, TPRN, SERPINB6, SiX1, CDH23, WHRN, OtoGL, WFS1, MYH9, REST, MCM2, DMXL2, TMIE, PCDH15, GRXCR1, TRIOBP, ILDR1, CIB2, GPSM2, ELMOD3, CABP2, TMEM132E, GRXCR2, EPS8, CLIC5, TRIOBP, ILDR1, SLC26A5, etc.) and gene therapy tools are targeted to cochlear hair cells to promote the expression of transgenes in hair cells, thereby compensating for the loss of related proteins and achieving the purpose of treating hereditary deafness.
[0074] Specific promoter
[0075] The inventors have discovered a promoter capable of specifically initiating gene expression in cochlear hair cells, comprising the sequence set forth in SEQ ID NO: 1 or a homologous sequence at least 90% identical thereto. Based on this, and in contrast to existing techniques, the present invention provides a cochlear hair cell-specific promoter and a therapeutic method specifically targeting cochlear hair cells. By utilizing this promoter, a viral vector containing this promoter can target a specific gene to cochlear hair cells, promoting transgene expression in these cells and thereby providing gene therapy for hearing loss caused by deafness gene mutations.
[0076] A promoter is a DNA sequence that RNA polymerase recognizes, binds to, and initiates transcription. It is located upstream of the start codon of a structural gene (usually within approximately 100 to 1000 bp) that controls transcription of the structural gene. It contains conserved sequences required for specific binding of RNA polymerase and initiation of transcription, but the promoter itself is not transcribed. Its general structure includes a core promoter element and upstream regulatory elements. The core promoter element refers to the minimal DNA sequence required for RNA polymerase to initiate transcription. The core promoter elements of eukaryotes include the transcription start site and the TATA box 25 to 30 bp upstream, which primarily serves as the site for RNA polymerase to bind and initiate transcription. When acting alone, the core promoter element can determine the transcription start site and produce a basal level of transcription. Upstream regulatory elements can alter the efficiency of transcription by binding to corresponding trans-acting factors.
[0077] In some embodiments, the cochlear hair cell-specific promoter of the present invention comprises: (1) an enhancer sequence as set forth in SEQ ID NO: 2 or a sequence having at least 90% sequence identity thereto and retaining the function of SEQ ID NO: 2, and (2) a core promoter element as set forth in SEQ ID NO: 3 or a homologous sequence having at least 90% sequence identity thereto. In one or more embodiments, the enhancer sequence (1) is located upstream or downstream of the core promoter element (2).
[0078] Herein, the specific promoter can act as a promoter to specifically direct gene expression in cochlear hair cells, and (2) the core promoter element is a core promoter element suitable for initiating gene expression in mammalian cells. Those skilled in the art can easily obtain the sequences of these core promoter elements. According to some embodiments, the homologous sequence described in (2) is the sequence of the core promoter element of the SHH gene of a mammal, preferably a primate, and more preferably a hominid.
[0079] In one or more embodiments, the promoter comprises the sequence set forth in SEQ ID NO: 1 or a sequence having at least 90% sequence identity thereto.
[0080] In one or more embodiments, the sequence shown in SEQ ID NO: 1 consists of two sequences, one of which is derived from the human genome sequence as shown in SEQ ID NO: 2. The other is derived from the core promoter element of the human SHH gene, whose sequence is shown in SEQ ID NO: 3.
[0081] The present invention also relates to homologous sequences having at least 50%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, or at least 99% identity to the above-mentioned nucleic acid sequences (e.g., sequences of the components of a specific promoter). As used herein, "homologous sequence" refers to a sequence from a species of the same order, family, genus, or species as the species from which the sequence originated and having the sequence identity.
[0082] The present invention also relates to polynucleotides that hybridize to the sequence of the specific promoter described above and have at least 50%, preferably at least 70%, and more preferably at least 80% identity between the two sequences. The present invention particularly relates to polynucleotides that hybridize to the polynucleotide of the present invention under stringent conditions. In the present invention, "stringent conditions" refer to: (1) hybridization and elution at relatively low ionic strength and relatively high temperature, such as 0.2×SSC, 0.1% SDS, 60°C; or (2) the addition of a denaturing agent during hybridization, such as 50% (v / v) formamide, 0.1% calf serum / 0.1% Ficoll, 42°C; or (3) hybridization occurs only when the identity between the two sequences is at least 90%, more preferably at least 95%.
[0083] Nucleic acid constructs
[0084] The present invention also provides the nucleic acid construct comprising the above-mentioned specific promoter for cloning or expressing genetic functions such as genes. The nucleic acid construct can be an expression cassette or a vector. Therefore, in addition to the specific promoter, the nucleic acid construct can also include other elements required for cloning or expression, such as a multiple cloning site and / or a terminator (e.g., a polyA signal sequence). For example, the nucleic acid construct can be an RNA construct or a DNA vector that can be transfected into cells and expressed. Herein, "nucleic acid molecule," "polynucleotide," and "nucleic acid" are used interchangeably.
[0085] In order to express a polypeptide or protein, the nucleic acid construct further comprises a gene of interest, which is operably linked to the specific promoter. Herein, the gene can be a coding sequence that can encode a polypeptide or protein. In some embodiments of the present invention, the gene is selected from the group consisting of: (1) ATOH1, VGLUT3, TMC1 / 2, KCNQ1, MLRB3, LHFPL5, OTOF, STRC, MYO7A, CHD7, TMPRSS3, POU3F4, ESPN, SYNE4, DIAPH1, KCNQ4, CEACAM16, MYO6, P2RX2, SMAC, TBC1D24, CD164, OSBPL2, HOMER2, MYO3A, PDE1C, SCD5 、USH1C、RDX、DCDC2、LOXHD1、TPRN、SERPINB6、SiX1、CDH23、WHRN、OtoGL、WFS1、MYH9、REST、MCM2、DMXL2、TMIE、PCDH15、GRXCR1、TRIOBP、ILDR1、CIB2、GPSM2、ELMOD3、CABP2、TMEM132E、GRXCR2、EPS8、CLIC5、TRIOBP、ILDR1、SLC26A5。The gene can also be a variety of tool genes for operating the genes of cochlear hair cells or expressed in cochlear hair cells, such as CRSPR-Cas system, Talen, ZFN and other gene editing tools, as well as shRNA, DNA / RNA base editing system, Prime editing and other technologies involved in the tool gene, such as gRNA, Cas enzyme protein expression gene. These technologies and tool genes are common knowledge for those skilled in the art. The polynucleotides described herein can be operably linked to therapeutic transgenes to provide a theoretical basis for clinical targeted treatment of hereditary hearing loss.
[0086] In the case where a gene or its sequence is known, the coding nucleic acid of each gene can be prepared using a method conventional in the art, and a corresponding vector can be constructed. Methods well known to those skilled in the art can be used to construct recombinant vectors, referring to, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory), Ausubel et al. (1989, Short Protocols in Molecular Biology, Wiley) or the technology described in other standard textbooks. Alternatively, the nucleic acid construct can be reconstructed into a liposome for delivery to a target cell. Containing the nucleic acid construct of the present invention can be transferred to a host cell by a well-known method, which varies according to the type of the cell host. For example, calcium chloride transfection is commonly used for prokaryotic cells, and calcium phosphate treatment or electroporation can be used for other cell hosts, referring to Sambrook et al. (see above).
[0087] The vectors described herein contain nucleic acid molecules or expression cassettes as described herein. The vector can be a plasmid, a cosmid, a virus, or a viral vector. The vector includes a cloning vector, an integration vector, or an expression vector. The expression vector typically contains sequences for plasmid maintenance and for cloning and expressing exogenous nucleotide sequences. The sequences (collectively referred to as "flanking sequences" in certain embodiments) typically include one or more of the following nucleotide sequences: a promoter (e.g., a specific promoter as described herein), one or more enhancer sequences, an origin of replication, a transcription termination sequence, a complete intron sequence containing donor and acceptor splice sites, a sequence encoding a leader sequence for polypeptide secretion, a ribosome binding site, a polyadenylation sequence, a multiple cloning site for inserting a nucleic acid encoding a protein to be expressed, and a selectable marker element. Typically, the promoter is located at the 5' end of the multiple cloning site or the polypeptide coding sequence. In one or more embodiments, the expression vector uses an AAV series vector as a backbone.
[0088] The vector may optionally contain a "tag" coding sequence, i.e., an oligonucleotide molecule located at the 5' or 3' end of the polypeptide coding sequence; the oligonucleotide sequence encodes polyhistidine (such as 6His) or another "tag" such as FLAG, HA or myc. This tag is typically fused to the polypeptide when the polypeptide is expressed and can serve as a means for affinity purification or detection of the protein from the host cell. Affinity purification can be accomplished, for example, by column chromatography using antibodies against the tag as an affinity matrix. The tag can optionally be subsequently removed from the purified protein by various means, such as using certain peptidases for cleavage.
[0089] The flanking sequences may be homologous (i.e., from the same species and / or strain as the host cell), heterologous (i.e., from a species other than the host cell species or strain), hybrid (i.e., a combination of flanking sequences from more than one source), synthetic, or natural. Likewise, the source of the flanking sequences may be any prokaryotic or eukaryotic organism, any vertebrate or invertebrate organism, or any plant, provided that the flanking sequences function in and can be activated by the host cell machinery.
[0090] Selectable marker genes encode a protein that is essential for the survival and growth of host cells grown in selective culture media. Typical selectable marker genes encode (a) resistance to antibiotics or other toxins (e.g., ampicillin, tetracycline, or kanamycin for prokaryotic host cells); (b) supplement the auxotrophic deficiency of the cell; or (c) provide a protein that is not available from a complex or defined culture medium for an important nutrient. Specific selectable markers are kanamycin resistance genes, ampicillin resistance genes, and tetracycline resistance genes. Advantageously, the neomycin resistance gene can also be used for selection in prokaryotic and eukaryotic host cells.
[0091] AAV vectors and AAV particles
[0092] As used herein, the term "adeno-associated virus" or "AAV" includes members of the class of viruses associated with that name, which belongs to the genus Dependoparvovirus, family Parvoviridae. Adeno-associated virus is a single-stranded DNA virus that grows exclusively in cells, where certain functions are provided by a co-infecting helper virus. General information and a review of AAV can be found, for example, in Carter, 1989, Handbook of Parvoviruses, Volume 1, pages 169-228. Various serotypes of this virus are known to be suitable for gene delivery, and the various serotypes are closely related structurally and functionally. All AAV serotypes apparently exhibit very similar replication characteristics mediated by homologous rep genes; and all carry three related capsid proteins. At least 13 sequentially numbered AAV serotypes are known in the art. Non-limiting exemplary serotypes that can be used in the methods disclosed herein include any of the 13 serotypes, such as AAV2, AAV8, and AAV9. AAV particles comprise, consist essentially of, or consist of the following three major viral proteins: VP1, VP2, and VP3. In one or more embodiments, AAV refers to serotype AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVPHP.B, or AAVrh74.
[0093] In some embodiments, the nucleic acid construct of the present invention is a pAAV vector that expresses a gene of interest via a recombinant AAV vector system. As used herein, "pAAV vector" refers to a vector comprising, essentially consisting of, or consisting of a specific promoter and one or more AAV inverted terminal repeats (ITRs) as described herein. When present in a host cell that provides functionality of the rep and cap gene products, such a pAAV vector can be replicated and packaged into infectious viral particles; for example, by transfecting the host cell. In one or more embodiments, the pAAV vector contains a specific promoter as described herein, at least one nucleic acid encoding at least one protein or RNA, and / or an enhancer and / or terminator packaged into the flanking ITRs of infectious AAV particles. The plasmid containing the pAAV vector may also contain elements for preparation purposes, such as antibiotic resistance genes and the like.
[0094] The present invention also provides an AAV vector system comprising the pAAV vector and other nucleic acid constructs encoding genes required by the AAV virus, wherein the pAAV vector comprises a specific promoter as described in any embodiment herein. In one or more embodiments, the pAAV vector further comprises a gene of interest as described herein, which is operably linked to the specific promoter. In one or more embodiments, the AAV vector system comprises an Anc80L65 plasmid, a helper plasmid, and the pAAV vector.
[0095] As used herein, the term "viral capsid" or "capsid" refers to the protein shell or capsid of the virus particle. The function of the capsid is to encapsidate, protect, transport the viral genome, and release it into the host cell. The capsid is generally composed of oligomeric structural subunits of proteins ("capsid proteins"). As used herein, the term "encapsid" refers to being contained within the viral capsid. The viral capsid of AAV is composed of a mixture of three viral capsid proteins: VP1, VP2, and VP3.
[0096] "AAV viral particle" or "AAV particle" refers to a viral particle composed of at least one AAV capsid protein and the encapsidated polynucleotide pAAV vector. Therefore, the production of AAV particles necessarily includes the production of pAAV vectors, as such vectors are contained within AAV particles. The present invention provides an AAV viral particle comprising a specific promoter as described herein, and optionally further comprising a gene of interest operably linked to the specific promoter.
[0097] As used herein, the term "helper" with respect to a virus or plasmid refers to a virus or plasmid that is used to provide additional components necessary for replication and packaging of any of the pAAV vectors disclosed herein. The components encoded by the helper virus can include any genes required for virion assembly, encapsidation, genome replication and / or packaging. For example, the helper virus or plasmid can encode enzymes necessary for viral genome replication. Non-limiting examples of helper viruses and plasmids suitable for use with pAAV constructs include pHelper (plasmid), adenovirus (virus), or herpes virus (virus).
[0098] Methods for producing and using AAV vectors are known in the art. Methods for producing AAV particles and heterologous nucleic acids are also known in the art and are commercially available (see, for example, US 2007 / 0015238 and US2012 / 0322861, which are incorporated herein by reference in their entirety). For example, a plasmid comprising a heterologous nucleic acid sequence can be combined with one or more helper plasmids (e.g., comprising rep genes (e.g., encoding Rep78, Rep68, Rep52, and Rep40) and cap genes (encoding VP1, VP2, and / or VP3) and transfected or permanently integrated into a production cell line so that the AAV particles can be packaged and subsequently purified.
[0099] In some embodiments, the one or more helper plasmids include a first helper plasmid comprising a rep gene and a cap gene and a second helper plasmid comprising an E1a gene, an E1b gene, an E4 gene, an E2a gene, and a VA gene. In some embodiments, the rep gene is a rep gene derived from AAV2, and the cap gene is derived from AAV44.9. Helper plasmids and methods for preparing such plasmids are known in the art and are commercially available.
[0100] cell
[0101] The present invention also includes host cells that contain or have integrated into their genome the specific promoters or nucleic acid constructs described herein. Host cells can be used as recipients of vectors. Host cells can be "transfected" or "transformed," which refers to the process by which exogenous nucleic acids are transfected or transduced into host cells. Transformed cells include the primary subject cell and its progeny. As used herein, the terms "engineered" and "recombinant" cells or host cells often refer to cells into which exogenous nucleic acid sequences, such as vectors, have been introduced. Thus, recombinant cells can be distinguished from naturally occurring cells that do not contain the introduced recombinant nucleic acids.
[0102] Suitable host cells are as described above, including but not limited to Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (eg, HepG2), cochlear hair cells, and the like.
[0103] As used herein, packaging cells (or helper cells) are cells for producing viral vectors. Production of recombinant AAV viral vectors requires trans-provided Rep and Cap proteins and the gene sequence of the helper AAV replication from adenovirus. In some aspects, packaging / helper cells contain a plasmid stably integrated into the cell genome. In other aspects, packaging cells can be transiently transfected. Typically, packaging cells are eukaryotic cells, such as mammalian cells or insect cells. In one or more embodiments, the cell for producing viral vectors is a HEK293 cell, including HEK293T, HEK293H, HEK293F, HEK293S, HEK293T / 17, HEK293T / 17SF, HEK293FT, HEK293SG, HEK293E, HEK293-6E, HEK293FTM, HEK293SGGD cells.
[0104] The nucleic acid construct / recombinant expression vector of the present invention can be transferred into the cell of interest. The method of transfer is conventional in the art, including but not limited to: viral transduction, microinjection, particle bombardment, gene gun transformation and electroporation. In certain embodiments, electroporation is used to transfer the nucleic acid construct or recombinant expression vector. When the host cells are cultured under appropriate conditions, the fusion protein is synthesized, and the fusion protein can then be collected from the culture medium (if the host cells secrete it into the culture medium) or directly from the host cells that produce it (if it is not secreted).
[0105] Methods for preparing AAV vectors and viruses
[0106] A variety of methods can be used to prepare AAV viral vectors. In one or more embodiments, packaging is achieved by using a helper virus or helper plasmid and a cell line. The helper virus or helper plasmid contains elements and sequences that promote the production of the viral vector. In some embodiments, the helper plasmid is stably integrated into the genome of the packaging cell line, so that the packaging cell line does not require additional transfection with the helper plasmid.
[0107] In one or more embodiments, the cell is a packaging cell line or a helper cell line. In one or more embodiments, the helper cell line is a eukaryotic cell; for example, HEK 293 cells or 293T cells. In one or more embodiments, the helper cell is a yeast cell or an insect cell.
[0108] The helper plasmid can comprise, for example, at least one viral helper DNA sequence derived from a replication-incompetent viral genome encoding trans-acting full virion proteins required for packaging replication-incompetent AAV, and virion proteins for producing virions capable of packaging replication-incompetent AAV at high titers without producing replication-incompetent AAV.
[0109] Helper plasmids for packaging AAV are known in the art, see, for example, U.S. Patent Publication No. 2004 / 0235174A1, which is incorporated herein by reference. As described therein, as a non-limiting example, an AAV helper plasmid may contain the Ad5 genes E2A, E4, and VA as helper viral DNA sequences, controlled by their respective native promoters or heterologous promoters. The AAV helper plasmid may additionally contain an expression cassette for expressing a marker protein, such as a fluorescent protein, to allow easy detection of transfection of desired target cells.
[0110] Provided herein are methods for producing AAV particles, comprising transfecting a packaging cell line with any of the AAV helper plasmids disclosed herein; and any of the AAV vectors disclosed herein. In some embodiments, the AAV helper plasmid and the AAV vector are co-transfected into the packaging cell line. In some embodiments, the cell line is a mammalian cell line, such as a human embryonic kidney (HEK) 293 cell line. Provided herein are cells comprising any of the AAV vectors and / or AAV particles disclosed herein.
[0111] Pharmaceutical composition
[0112] The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and one or more selected from the following: a specific promoter, a nucleic acid construct, an AAV vector system, an AAV viral particle, and a host cell as described herein. In one or more embodiments, the pharmaceutical composition comprises a pAAV vector and a pharmaceutically acceptable excipient, wherein the pAAV vector comprises a specific promoter as described herein operably linked to a gene of interest. In one or more embodiments, the pharmaceutical composition comprises an AAV viral particle and a pharmaceutically acceptable excipient, wherein the AAV viral particle comprises a polynucleotide comprising a specific promoter as described herein operably linked to a gene of interest.
[0113] As used herein, the term "pharmaceutically acceptable excipient" encompasses any standard pharmaceutical carrier, such as phosphate-buffered saline solution, water, and emulsions, such as oil / water or water / oil emulsions, and various types of wetting agents. The composition may also include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see Martin (1975) Remington's Pharm. Sci. 15th Edition (Mack Publ. Co., Easton).
[0114] As described herein, pharmaceutical compositions can be formulated by any method known or developed in the art of pharmacology, including but not limited to contacting the active ingredient (e.g., viral particles or recombinant vectors) with excipients or other auxiliary ingredients, dividing or packaging the product into dosage units. The viral particles herein can be formulated to have desired characteristics, such as increased stability, increased cell transfection, sustained or delayed release, biodistribution or tropism, modulation or enhanced translation of the encoded protein in vivo, and release profile of the encoded protein in vivo.
[0115] Thus, the pharmaceutical composition can further comprise saline, lipidoids, liposomes, lipid nanoparticles, polymers, lipid complexes, core-shell nanoparticles, peptides, proteins, cells transfected with viral vectors (e.g., for transplantation into a subject), nanoparticle mimics, or combinations thereof. In some embodiments, the pharmaceutical composition is formulated as nanoparticles. In some embodiments, the nanoparticles are self-assembled nucleic acid nanoparticles.
[0116] According to the pharmaceutical composition herein, it can be prepared, packaged and / or sold in bulk with a single unit dose and / or with multiple single unit doses. The amount of the active ingredient is generally equal to the dosage of the active ingredient to be administered to the subject and / or the appropriate ratio of such dosage, for example, half or one-third of such dosage. The preparation of the present invention may include one or more excipients, and the amount of each excipient together increases the stability of the viral vector, increases cell transfection or viral vector transduction, increases the expression of the protein encoded by the viral vector, and / or changes the release profile of the protein encoded by the viral vector. In some embodiments, the pharmaceutical composition includes an excipient. Non-limiting examples of an excipient include a solvent, a dispersion medium, a diluent or other liquid vehicle, a dispersion or suspension aid, a surfactant, an isotonic agent, a thickener or an emulsifier, a preservative or a combination thereof.
[0117] In some embodiments, the pharmaceutical composition comprises a cryoprotectant. The term "cryoprotectant" refers to an agent that can reduce or eliminate damage to a substance during freezing. Non-limiting examples of cryoprotectants include sucrose, trehalose, lactose, glycerol, dextrose, raffinose, and / or mannitol.
[0118] Uses and methods
[0119] The present invention provides use of the specific promoter in preparing a drug for treating a disease caused by a gene defect in cochlear hair cells, wherein the drug is used for expressing the gene in the cochlear hair cells.
[0120] Provided herein are methods for introducing a gene of interest into a cell of a subject, comprising contacting the cell with an effective amount of any of the AAV viral particles described herein, wherein the particle comprises a polynucleotide comprising a specific promoter described herein operably linked to the gene of interest.
[0121] The present invention provides a method for expressing a gene of interest in cochlear hair cells, comprising the step of introducing a nucleic acid construct comprising the gene into the cochlear hair cells, wherein the gene is operably linked to a specific promoter as described herein. Typically, the promoter is in frame with the gene and located upstream of the gene. Examples of genes of interest are described elsewhere herein.
[0122] The specific promoter described herein is operably linked to a therapeutic gene, providing a theoretical basis for the clinical targeted treatment of hereditary hearing loss. The present invention provides a method for treating a disease caused by a gene defect in cochlear hair cells, comprising the step of expressing the gene in the cochlear hair cells, wherein the gene is operably linked to the cochlear hair cell-specific promoter described herein. The method comprises the step of introducing a nucleic acid construct or vector comprising the coding sequence of the gene into the cochlear hair cells, wherein the coding sequence of the gene is operably linked to the specific promoter. Exemplarily, the gene is selected from: a deafness gene, a tool gene for operating the genes of the cochlear hair cells, or expressed in the cochlear hair cells. In one or more embodiments, the deafness gene is a deafness gene expressed by the cochlear hair cells. In one or more embodiments, the deafness gene is a pathogenic gene for non-syndromic deafness. In one or more embodiments, the deafness genes include one or more selected from the group consisting of ATOH1, VGLUT3, TMC1 / 2, KCNQ1, MLRB3, LHFPL5, OTOF, STRC, MYO7A, CHD7, TMPRSS3, POU3F4, ESPN, SYNE4, DIAPH1, KCNQ4, CEACAM16, MYO6, P2RX2, SMAC, TBC1D24, CD164, OSBPL2, HOMER2, MYO3A, PD E1C, SCD5, USH1C, RDX, DCDC2, LOXHD1, TPRN, SERPINB6, SiX1, CDH23, WHRN, OtoGL, WFS1, MYH9, REST, MCM2, DMXL2, TMIE, PCDH15, GRXCR1, TRIOBP, ILDR1, CIB2, GPSM2, ELMOD3, CABP2, TMEM132E, GRXCR2, EPS8, CLIC5, TRIOBP, ILDR1, SLC26A5. The disease is hereditary deafness caused by a gene defect in cochlear hair cells. Preferably, the disease is sensorineural hearing loss. Herein, "hearing loss" and "deafness" are used interchangeably. Congenital deafness in sensorineural deafness includes non-hereditary and hereditary types. Among them, 70% of hereditary patients do not have other symptoms besides deafness, which is called non-syndromic deafness. Therefore, sensorineural hearing loss includes congenital hearing loss and non-congenital hearing loss.
[0123] The term "disease and / or condition" refers to the physical state of a subject associated with a disease and / or condition described herein. As used herein, "treatment" includes any beneficial or desired effect on the symptoms or changes of a disease or pathological condition, and may include even a small reduction in one or more measurable markers of the disease or condition being treated (e.g., a hereditary deafness disease). Treatment may optionally include a reduction or alleviation of the symptoms of the disease or condition, or a delay in the progression of the disease or condition. "Treatment" does not necessarily mean complete eradication or cure of the disease or condition or its associated symptoms. As used herein, "treatment" of a disease in a subject means (1) preventing the occurrence of symptoms or disease in a subject who is susceptible to or does not yet exhibit symptoms of the disease; (2) inhibiting the disease or arresting its development; or (3) ameliorating or causing regression of the disease or disease symptoms. As understood in the art, "treatment" is an approach used to obtain beneficial or desired results, including clinical results. Beneficial or desired results may include one or more of, but are not limited to, alleviation or amelioration of one or more symptoms, whether detectable or undetectable, lessening of the extent of a condition (including a disease), a stable (i.e., not worsening) state of a condition (including a disease), a delay or slowing of a condition (including a disease), progression, improvement or palliation of a condition (including a disease), state, and remission (whether partial or total).
[0124] The term "subject" or "patient" may refer to a cell or animal, such as a mammal or human, that receives a pharmaceutical composition of the present invention to treat, prevent, ameliorate, and / or alleviate a disease or condition of the present invention. The subject is not limited to a particular species and includes non-human animals receiving diagnosis or treatment and those receiving infection or animal models, including but not limited to dog, monkey, cow, horse, ape, mouse, rat, canine, or lagomorphic species, as well as other livestock, sports animals, or pets. In some embodiments, the subject is human.
[0125] As used herein, the term "effective amount" is intended to mean an amount sufficient to achieve the desired effect. In the case of therapeutic or preventive applications, the effective amount will depend on the type and severity of the disorder in question and the characteristics of the individual subject, such as general health, age, sex, weight, and tolerance to the pharmaceutical composition. In the context of gene therapy, in some embodiments, the effective amount is an amount sufficient to restore some or all of the function of a defective gene in a subject. In other embodiments, the effective amount of AAV viral particles is an amount sufficient to cause gene expression in a subject. In some embodiments, the effective amount is the amount required to increase galactose metabolism in a subject in need. A skilled technician will be able to determine the appropriate amount based on these and other factors.
[0126] In some embodiments, the effective amount will depend on the size and nature of the application in question. It also depends on the nature and sensitivity of the target subject and the method of use. Those skilled in the art will be able to determine the effective amount based on these and other considerations. According to embodiments, the effective amount can include, consist essentially of, or consist of one or more administrations of the composition.
[0127] As used herein, the term "administering" is intended to mean delivering a substance to a subject, such as an animal or a human. Administration can be performed in one dose, continuously, or intermittently throughout the course of treatment. Methods for determining the most effective mode of administration and dosage are known to those skilled in the art and will vary with the composition used for treatment, the therapeutic purpose, and the age, health, or sex of the subject being treated. Single or multiple administrations can be performed, with the dosage level and pattern being selected by the treating physician, or in the case of pets and other animals, by the treating veterinarian.
[0128] Dosage and administration
[0129] Methods for determining the most effective mode of administration and dosage are known to those skilled in the art and will vary with the composition used for treatment, the purpose of the treatment, and the subject being treated. Single or multiple administrations may be performed, with the dosage level and pattern being selected by the treating physician. Dosage may be affected by the route of administration. Suitable dosage formulations and methods of administering the agents are known in the art. Non-limiting examples of such suitable dosages may range from as little as 10E9 vector genomes to as much as 10E17 vector genomes per administration.
[0130] In embodiments of the methods described herein, the number of viral particles (e.g., AAV) administered to a subject ranges from about 10E9 to about 10E17. In certain embodiments, about 10E10 to about 10E12, about 10E11 to about 10E13, about 10E11 to about 10E12, about 10E11 to about 10E14, about 5×10E11 to about 5×10E12, or about 10E12 to about 10E13 viral particles are administered to a subject.
[0131] In some embodiments, the AAV particles repair a genetic defect in a subject. In some embodiments, the ratio of repaired target polynucleotides (e.g., Myo7a, STRC, OTOF) or polypeptides to unrepaired target polynucleotides or polypeptides in successfully treated cells, tissues, organs, or subjects is at least about 1.5:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 20:1, about 50:1, about 100:1, about 1000:1, about 10,000:1, about 100,000:1, or about 1,000,000:1. The amount or ratio of repaired target polynucleotides or polypeptides can be determined by any method known in the art, including but not limited to Western blotting, Northern blotting, Southern blotting, PCR, sequencing, mass spectrometry, flow cytometry, immunohistochemistry, immunofluorescence, fluorescence in situ hybridization, sequencing, immunoblotting, and ELISA.
[0132] In some embodiments, the viral particles are introduced into the subject intravenously, intrathecally, intracerebrally, intraventricularly, intranasally, intratracheally, intraaurally, intraocularly or periocularly, orally, rectally, transmucosally, by inhalation, transdermally, parenterally, subcutaneously, intradermally, intramuscularly, intrapleurally, topically, intralymphatically, intracisternally; such introduction can also be intraarterially, intracardially, subventricularly, epidurally, intracerebrally, intraventricularly, subretinally, intravitreally, intraarticularly, intraperitoneally, intrauterinely, or any combination thereof. In some embodiments, the delivery of the viral particles is systemic.
[0133] Administration of the AAV vectors, AAV particles, or compositions of the present disclosure can be achieved in one dose, continuously, or intermittently throughout the course of treatment. In some embodiments, the AAV vectors, AAV particles, or compositions of the present disclosure are administered parenterally by injection, infusion, or implantation. The AAV particles and compositions of the present disclosure can be administered in combination with other known treatments for the condition being treated.
[0134] Reagent test kit
[0135] In some embodiments, the specific promoters, nucleic acid constructs, cells, viral particles, or pharmaceutical compositions described herein can be assembled into pharmaceutical or diagnostic or research kits to facilitate their use in therapeutic, diagnostic, or research applications. In some embodiments, the kits of the present disclosure include any of the AAV vectors, AAV particles, cells, or pharmaceutical compositions described herein.
[0136] In some embodiments, the test kit also includes instructions for use. Specifically, such a test kit can include one or more reagents as described herein, and instructions for the intended application and correct use of these reagents. In some embodiments, the test kit can include instructions for mixing one or more components of the test kit and / or separating and mixing samples and applying to a subject. In some embodiments, the reagent in the test kit is a pharmaceutical formulation and dosage suitable for a specific application and the method of administration of the reagent. The test kit can contain the components of the appropriate concentration or amount for carrying out various experiments for research purposes.
[0137] Kit can be designed to facilitate the use of the methods described herein, and can take many forms. Where applicable, every kind of composition of kit can be provided in liquid form (e.g., in solution) or in solid form (e.g., dry powder). In some cases, some compositions can be constructible or processable in addition (e.g., processed into active form), for example, by adding suitable solvent or other substances (e.g., water or cell culture medium), which may or may not be provided together with kit. In some embodiments, composition can be provided in a preservation solution (e.g., a cryopreservation solution). The non-limiting examples of a preservation solution include DMSO, paraformaldehyde. In some embodiments, the preservation solution contains a certain amount of metalloproteinase inhibitors.
[0138] In some embodiments, the test kit contains any one or more components as described herein in one or more containers. Therefore, in some embodiments, the test kit can include a container for holding a reagent as described herein. The reagent can be in the form of a liquid, gel, or solid (powder). The reagent can be aseptically prepared, packaged in a syringe, and transported frozen. Alternatively, they can be contained in a bottle or other container for storage. A second container can have other reagents of aseptic preparation. Alternatively, the test kit can include a premixed active agent and transported in a syringe, bottle, tube, or other container. The test kit can have one or more or all components required for administering the reagent to the subject, such as a syringe, a local application device, or an IV needle and bag.
[0139] The present invention will be described below by way of specific examples. It should be understood that these examples are merely illustrative and are not intended to limit the scope of the present invention. The methods and materials used in the examples are, unless otherwise stated, conventional materials and methods in the art.
[0140] Example
[0141] Example 1: Specific promoter promotes expression of reporter gene in cochlear hair cells
[0142] 1.1 Construction of the specific promoter Otov-HC plasmid and viral packaging
[0143] The specific promoter Otov-HC (SEQ ID NO: 1) was constructed into the pAAV-mNeonGreen-Bpnls plasmid (flanked by AAV2 inverted terminal repeat sequences) (SEQ ID NO: 7). mNeonGreen (DNA sequence: SEQ ID NO. 4, amino acid sequence: SEQ ID NO. 5) is a green fluorescent protein used to indicate infected and expressing cells. Otov-HC (SEQ ID NO: 1) was synthesized by GenScript and incorporated into the fluorescent protein mNeonGreen using the restriction enzymes XbaI and EcoRI. The resulting pAAV-Otov-HC-mNeonGreen-Bpnls (SEQ ID NO: 8) viral packaging plasmid was co-transfected with the capsid protein fusion plasmid pAAV-ie-rep-cap (SEQ ID NO: 10) provided by our laboratory (plasmid information is available in the literature doi: 10.1038 / s41467-019-11687-8) and the pHelper helper plasmid (NCBI No. AF3699965.1) in appropriate amounts into HEK-293T cells. AAV virus was purified by iodixanol gradient centrifugation, with a viral titer of 1E12–1E13 GC / mL.
[0144] 1.2 Targeted driving effect of specific promoter on mNeonGreen in cochlear hair cells
[0145] Two AAV-i.e., Otov-HC-mNeonGreen-Bpnls, containing specific promoters, were injected into the inner ears of P2-P3 (postnatal day 2-3) mice via the round window. Mice were anesthetized on ice for 1-2 minutes. After anesthesia, a retroauricular incision was made to expose the round window. The cochlea was then manually injected using a glass micropipette. A volume of 6E10 g of virus was injected into each ear. After injection, the skin incision was sealed with 3M Vethod tissue glue. The injected mice were then placed on a 37°C heating pad for recovery. Newborn mice fully recovered within approximately 10 minutes and were returned to their mothers. Standard postoperative care was followed. Two weeks later, the infection efficiency of cochlear hair cells was assessed and statistically analyzed. Immunofluorescence staining of the mouse cochlea was performed using antibodies against the hair cell marker Myo7a, the supporting cell marker Sox2, and the nuclear marker DAPI. Before cochlear mounting, the cochlea was fixed and decalcified. After dissection and removal of the tectorial membrane, the cochlea was washed three times with PBS, blocked with Block solution for 1 hour, and then incubated with the primary antibody (1:1000 Myo7a) at 4°C overnight. The tissue was washed three times with PBS and counterstained with secondary antibodies (1:4000 Donkey anti-rabbit Alexa Fluor 555 and 1:1000 DAPI) at room temperature for 1 hour. The tissue was washed three times with PBS. The slides were removed, labeled with mouse information and cochlear processing procedures, and antifade reagent was added to the slides. The slides were gently covered with a coverslip, avoiding air bubbles during the process, and stored in a cool, dark place. Confocal images were acquired on a Zeiss LSM700 laser confocal microscope. Images of the entire cochlea were processed using ImageJ software. The acquired images were projected along the z-axis using ImageJ. The number of cells double-positive for Myo7a-labeled HCs and mNeonGreen was counted. Immunofluorescence staining results showed that the mNeonGreen reporter gene was specifically expressed only in cochlear hair cells (Figure 2).
[0146] Example 2: CAG (SEQ ID NO: 6) is a broad promoter driving reporter gene expression in cochlear cells
[0147] The same method as in Example 1 was used to construct the pAAV-CAG-mNeonGreen-Bpnls plasmid and produce the virus.
[0148] Using the same method as in Example 1, round window membrane virus was injected into wild-type mice at P2 (day 2 after birth), and immunofluorescence staining experiments were performed at P14. The virus injection volume per mouse ear was 6E10GC. The results are shown in Figure 1, indicating that AAV-ie-CAG-mNeonGreen-Bpnls can achieve 100% infection efficiency in the cochlear hair cells of newborn mice and more than 75% infection efficiency in supporting cells.
[0149] Example 3: The SHH sequence alone (SEQ ID NO: 3) does not drive gene expression in cochlear cells
[0150] 3.1 Plasmid construction and viral packaging
[0151] SHH (SEQ ID NO: 3) was incorporated into the pAAV-mNeonGreen-Bpnls (SEQ ID NO: 7) plasmid to construct the pAAV-SHH-mNeonGreen-Bpnls (SEQ ID NO: 9) viral packaging plasmid. This was co-transfected with the AAV-ie capsid protein plasmid and pHelper plasmid at appropriate amounts into HEK-293T cells. AAV virus was purified by iodide gradient ultracentrifugation, and a viral titer of 1E+12 to 1E+13 GC / mL was considered appropriate.
[0152] 3.2 SHH (SEQ ID NO: 3) alone cannot drive mNeonGreen expression in cochlear cells
[0153] Two AAV-i.e., SHH-mNeonGreen-Bpnls, containing specific promoters, were injected into the inner ears of mice at P2-P3 via the round window. Mice were anesthetized on ice for 1-2 minutes. After anesthesia, a retroauricular incision was made to expose the round window, and the cochlea was visually inspected and injected manually with a glass micropipette. After injection, the skin incision was sealed with 3M Method tissue glue. Two weeks later, the infection efficiency of cochlear hair cells was assessed and statistically analyzed. Immunofluorescence staining of the mouse cochlea with the hair cell marker myosin7a and the nuclear marker DAPI was performed. Before cochlear mounting, the cochlea was fixed and decalcified. After dissection and removal of the tectorial membrane, the cochlea was washed three times with PBS, blocked with Block solution for 1 hour, and then incubated with the primary antibody (1:1000 Myo7a) overnight at 4°C. The tissue was washed three times with PBS and counterstained with secondary antibodies (Donkey anti-rabbit Alexa Fluor 555 at 1:4000 and DAPI at 1:1000) for 1 hour at room temperature. The number of Myosin7a-labeled HCs and mNeonGreen-positive cells was counted. Immunofluorescence staining showed that the mNeonGreen reporter gene was not expressed in either cochlear hair cells or supporting cells (Figure 3). This indicates that Otov-HC (SEQ ID NO: 1) is specifically generated by SEQ ID NO: 2.
[0154] Example 4: Targeted driving effect of specific promoter on Otof gene (dual vector) and its efficacy verification
[0155] 4.1 Plasmid construction and viral packaging
[0156] Otof gene-mediated hearing loss is sensorineural non-syndromic deafness, which is expressed in cochlear hair cells. Because the Otof gene is too large, it is necessary to use the dual AAV vector pAAV-CMV-N-Otof-SD-AK plasmid (flanked by AAV2 inverted terminal repeats) (SEQ ID NO: 11) and pAAV-AK-SA-C-Otof plasmid (flanked by AAV2 inverted terminal repeats) (SEQ ID NO: 12) to deliver it to the inner ear hair cells. The specific promoter Otov-HC (SEQ ID NO: 1) was constructed into the pAAV-CMV-N-Otof-SD-AK plasmid (flanked by AAV2 inverted terminal repeats) (SEQ ID NO: 11). Plasmid construction was commissioned by GenScript, and the original CMV promoter was replaced with the Otov-HC-specific promoter (SEQ ID NO: 1) using the restriction endonucleases XhoI and EcoRI to construct the pAAV-Otov-HC-N-Otof-SD-AK viral packaging plasmid (SEQ ID NO: 13). This plasmid was co-transfected with the capsid protein fusion plasmid pAAV-ie-rep-cap (SEQ ID NO: 10) provided by our laboratory (plasmid information is available in the literature doi: 10.1038 / s41467-019-11687-8) and the pHelper helper plasmid (NCBI No. AF3699965.1) in appropriate amounts into HEK-293T cells. AAV virus was purified by iodixanol gradient centrifugation, and the virus titer was measured to be 1E12-1E13 GC / mL.
[0157] 4.2 Validation of drug efficacy in the Otof gene knockout mouse model
[0158] The same method as in Example 1 was used to inject the round window membrane virus into wild-type mice at P2 (day 2 after birth), with the virus injection volume of 6E10 GC per mouse ear. At P30, the auditory brainstem response (ABR) was used to detect the recovery of auditory function in Otof knockout mice after gene therapy. At the same time, audiometry was performed on homozygous knockout mice 30 days after birth and wild-type control mice of the same litter. ABR is mainly used to detect whether the function of all parts in the sound transmission process is normal. The sensory epithelium of the cochlea of WT, Otof- / - knockout mice and Otof- / - virus-injected mice after audiometry was microdissected and stained with Otoferlin (ab53233, 1:200, Abcam) and Alexa Fluor TM Immunolabeling was performed with 647 phalloidin antibody (Invitrogen, 1:100, A22287) to study the recombinant expression of the exogenous Otof gene driven by the specific promoter Otov-HC in the cochlear cells of KO mice (provided by Guangzhou Saiye Company).
[0159] The results showed that AAV-ie-Otov-HC-N-Otof-SD-AK and AAV-ie-AK-SA-C-Otof drove the specific expression of the exogenous Otof gene in the cochlear hair cells of newborn mice. The expression efficiency of recombinant Otof was close to that of the WT littermates, and the homozygous knockout mice in the same littermates did not express the Otof gene (Figure 4). Statistical results showed that after 30 days, the expression efficiency of the recombinant OTOF protein could still reach 100% in the 0-24kHz frequency band and more than 55% in the 24-32kHz frequency band (Figure 5). ABR results showed that after knocking out the Otof gene, the hearing threshold of the mice increased significantly at low, medium and high frequencies, and they were basically completely deaf, indicating that Otof plays an important role in the hearing of mice. Thirty days after injection, the treated Otof knockout mouse model showed a lower ABR threshold compared with the homozygous knockout mice in its littermates, and all hearing frequency bands were significantly restored. The hearing recovery effect was similar to that of the WT mice in its littermates, and the hearing threshold remained stable for a considerable period of one month (Figure 6).
[0160] sequence of this article
[0161] SEQ ID NO: 1: Otov-HC promoter sequence
[0162] SEQ ID NO: 2: Enhancer sequence
[0163] SEQ ID NO: 3: SHH gene core promoter element sequence
[0164] SEQ ID NO: 4: mNeonGreen DNA sequence
[0165] SEQ ID NO: 5: mNeonGreen amino acid sequence
[0166] SEQ ID NO: 6: CAG sequence
[0167] SEQ ID NO: 7: pAAV-mNeonGreen-Bpnls plasmid sequence
[0168] SEQ ID NO: 8: pAAV-Otov-HC-mNeonGreen-Bpnls plasmid sequence
[0169] SEQ ID NO: 9: pAAV-SHH-mNeonGreen-Bpnls plasmid sequence
[0170] SEQ ID NO: 10: pAAV-ie-rep-cap capsid plasmid sequence
[0171] SEQ ID NO: 11: pAAV-promotor-CMV-N-Otof-SD-AK plasmid sequence
[0172] SEQ ID NO: 12: pAAV-AK-SA-C-Otof-WPRE-SV40 plasmid sequence
[0173] SEQ ID NO: 13: pAAV-Otov-HC-N-Otof-SD-AK virus packaging plasmid sequence
Claims
1. A nucleic acid promoter comprising: (1) an enhancer sequence and (2) a core promoter element, wherein the enhancer sequence has a sequence as shown in SEQ ID NO: 2 or a homologous sequence having at least 90% sequence identity thereto and retaining the function of SEQ ID NO: 2, Preferably, the homologous sequence is a sequence of a mammal, preferably of the order Primates, more preferably of the family Hominidae.
2. The nucleic acid promoter according to claim 1, characterized in that (2) the core promoter element is the core promoter element of the SHH gene, Preferably, (2) the core promoter element has the sequence shown in SEQ ID NO: 3 or a homologous sequence having at least 90% sequence identity thereto, More preferably, the homologous sequence is a SHH gene sequence of a mammal, preferably a primate, more preferably a hominid.
3. The nucleic acid promoter according to claim 2, characterized in that The promoter comprises the sequence shown in SEQ ID NO: 1 or a sequence having at least 90% sequence identity thereto.
4. A nucleic acid construct comprising the promoter according to any one of claims 1 to 3. Preferably, The nucleic acid construct is a vector, and / or The nucleic acid construct further comprises a gene of interest, which is operably linked to the promoter. More preferably, the gene is selected from: a deafness gene, a tool gene for manipulating genes of cochlear hair cells or expressed in cochlear hair cells.
5. An AAV vector system comprising the nucleic acid construct of claim 4 and a nucleic acid construct encoding a gene required by the AAV virus, Preferably, The nucleic acid construct further comprises a gene of interest, which is operably linked to the specific promoter. The genes required for AAV virus packaging include one or more genes selected from the following: Rep, Cap, E2A, E4 and VA genes, More preferably, the AAV vector system comprises an AAV-ie plasmid, a pHelper plasmid and the nucleic acid construct of claim 4.
6. An AAV virus particle comprising the promoter according to any one of claims 1-3.
7. A host cell comprising or having integrated into its genome: the promoter according to any one of claims 1 to 3, the nucleic acid construct according to claim 4, or the AAV vector system according to claim 5, Preferably, the cells are cochlear hair cells.
8. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and one or more selected from the following: a promoter according to any one of claims 1 to 3, a nucleic acid construct according to claim 4, an AAV vector system according to claim 5, an AAV virus particle according to claim 6, and a host cell according to claim 7.
9. An in vitro method for expressing a gene in cochlear hair cells, comprising the steps of incubating the host cell of claim 7 under conditions suitable for gene expression, Preferably, the method further comprises the step of introducing a nucleic acid construct comprising the gene into cochlear hair cells, wherein the gene is operably linked to the specific promoter according to any one of claims 1 to 3.
10. Use of the sequence shown in SEQ ID NO: 2 or a homologous sequence having at least 90% sequence identity thereto and retaining the function of SEQ ID NO: 2 in a chimeric promoter.
11. A method for preparing a chimeric promoter, comprising: The (1) sequence shown in SEQ ID NO: 2 or a homologous sequence having at least 90% sequence identity thereto and retaining the function of SEQ ID NO: 2 is operably linked to (2) a core promoter element.
12. Use of the promoter according to any one of claims 1 to 3 in the preparation of a drug for treating a disease caused by a gene defect in cochlear hair cells, wherein the drug is used to express the gene in cochlear hair cells. Preferably, the gene is selected from: a deafness gene, various tool genes that operate on genes of cochlear hair cells or are expressed in cochlear hair cells, Preferably, the disease is hereditary deafness caused by a genetic defect in the cochlear hair cells. More preferably, the disease is sensorineural hearing loss.
13. A method for treating a disease caused by a gene defect in cochlear hair cells, comprising the step of expressing the gene in the cochlear hair cells of a subject, wherein the gene is operably linked to the promoter of any one of claims 1 to 3, Preferably, the method comprises the step of introducing into the cochlear hair cells a nucleic acid construct or vector comprising the coding sequence of the gene operably linked to the promoter. Preferably, the disease is hereditary deafness caused by a gene defect in the cochlear hair cells, More preferably, the disease is sensorineural hearing loss.
Citation Information
Patent Citations
Aav helper plasmids for helper virus-free packaging and pseudo typification of aav vectors
US20040235174A1
Production of pseudotyped recombinant AAV virions
US20070015238A1
Compositions and Methods for Treating Diseases
US20120322861A1
Materials and methods for delivering nucleic acids to cochlear and vestibular cells
CN111698975A
Compositions and methods for delivering nucleic acids to cochlear and vestibular cells
CN112423791A
Cited By
Pcdh15 gene enhancer and application thereof
CN120290568A
Compositions and methods for treating non-age-associated hearing impairment in a human subject
US12673116B2
